Vimgreen's A2A Receptor Antagonist VG081821 Receives First Global IND Approval for NASH Treatment
Key Insights
Vimgreen Pharmaceuticals (search) received China's CDE approval for VG081821 (search), marking the first global clearance of an A2A receptor antagonist for NASH (search) clinical investigation.
VG081821 (search) can proceed directly to Phase II trials, bypassing Phase I and significantly accelerating development timelines for this potential breakthrough therapy.
The drug targets all three core NASH (search) pathological features—steatosis, inflammation, and fibrosis—through its unique mechanism as the only A2A inverse agonist in global clinical development.
Vimgreen Pharmaceuticals (search) announced that China's Center for Drug Evaluation (CDE) has approved its Investigational New Drug (IND) application for VG081821 (search) in non-alcoholic steatohepatitis (NASH (search)), also known as metabolic dysfunction-associated steatohepatitis (MASH (search)). This approval represents the first global clearance of an A2A receptor antagonist for NASH clinical investigation and marks the second clinical indication for the company's lead drug candidate, which is already in development for Parkinson's disease.
Direct Path to Phase II Trials
The IND approval allows VG081821 (search) to proceed directly to Phase II NASH (search) trials, significantly shortening the clinical development timeline. Vimgreen expects to initiate a Phase IIa trial for NASH treatment in the second half of the year, positioning the company to accelerate delivery of this potential breakthrough therapy to patients.
Addressing Critical Unmet Medical Need
NASH (search) is a progressive liver disease characterized by excessive fat accumulation (steatosis), hepatocellular injury, inflammation, and progressive fibrosis. With obesity and metabolic syndrome reaching epidemic proportions worldwide, NASH has emerged as a leading cause of cirrhosis and hepatocellular carcinoma. Despite its increasing prevalence and severe clinical consequences, the therapeutic landscape remains highly limited, with only two pharmacological agents—resmetirom and semaglutide—having received accelerated approval to date.
Novel Mechanism of Action
As an A2A receptor antagonist, VG081821 (search) simultaneously targets the three core pathological features of NASH (search): steatosis, inflammation, and fibrosis. This multi-dimensional therapeutic approach offers distinct advantages given the complex pathophysiology of NASH. The drug's therapeutic potential is supported by compelling epidemiological evidence showing that moderate coffee consumption significantly reduces the risk of chronic liver disease, with caffeine exerting hepatoprotective effects primarily through A2A receptor inhibition.
VG081821 (search) distinguishes itself from traditional A2A receptor antagonists such as istradefylline through its unique pharmacological profile. While conventional antagonists simply block receptor activation, VG081821 is the only A2A inverse agonist currently in global clinical development, further suppressing the receptor's constitutive basal activity. This dual mechanism enables more complete inhibition of pathological signaling, potentially delivering superior pharmacological effects compared to standard antagonists.
Proven Clinical Experience
VG081821 (search)'s safety and efficacy profile has been established through its development in Parkinson's disease, where it represents the only investigational therapy globally that addresses both symptoms and underlying disease mechanisms. In completed Phase II trials of early-to-mid-stage Parkinson's disease, VG081821 demonstrated significant improvements in motor function, meeting all efficacy expectations and showing strong potential as a monotherapy.
The primary observed adverse event was transient elevation of liver transaminases, which researchers attribute to accelerated hepatic de-lipidation and enhanced gluconeogenesis rather than a toxic effect. Similar transient transaminase elevations have been observed with other lipid-modifying agents, including fibrates and resmetirom, and are generally considered benign adaptive physiological responses.
Company Leadership Perspective
"We are thrilled to receive the IND approval to advance VG081821 (search) for NASH (search) therapy," said Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals (search). "Its mechanism of action is highly differentiated from current THR-beta agonists and GLP-1 therapies. By leveraging the drug's unique ability to restore hepatic lipophagy while simultaneously resolving inflammation and fibrosis, we are well-positioned to address the substantial unmet need in metabolic liver diseases and poised to deliver superior patient outcomes."
About Vimgreen Pharmaceuticals
Vimgreen is a clinical-stage pharmaceutical company based in Hangzhou, China, dedicated to developing novel therapeutics targeting adenosine signaling pathways. The company focuses on addressing unmet medical needs in neurodegenerative, metabolic, and inflammatory diseases. Vimgreen's pipeline includes two clinical-stage compounds: VG081821 (search), an A2A receptor antagonist for Parkinson's disease and NASH (search); and VG290131, an A3 receptor agonist for autoimmune and inflammatory diseases.